TCON TRACON Pharmaceuticals Inc
9,467
$1.82
$0.01
(0.55%)
| Watchers | 9,467 |
| 52-Wk Low | $1.59 |
| 52-Wk High | $14.75 |
| Market Cap | $4.12M |
| Volume | 90,875.00 |
| 52-Wk High | $14.75 |
| 52-Wk Low | $1.59 |
TRACON Pharmaceuticals Provides Update on Ongoing ENVASARC Phase 2 Pivotal Trial Following Independent Data Monitoring Committee Recommendation to Continue the Trial as PlannedGlobe Newswire • about 1 month ago
ENVASARC Trial is Fully Enrolled and Final Data are Expected in Third Quarter 2024 SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage...
Share to Feed
Maxim Group analyst Jason McCarthy maintained a Buy rating on TRACON Pharmaceuticals (TCON Research Report) yesterday and set a price target of...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
SAN DIEGO, March 05, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development...
SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development...